Long-term Effectiveness and Safety of Eculizumab in Patients With Generalized Myasthenia Gravis (gMG): Real-world Data From Japan (S34.006)
To report the third-year analysis from the postmarketing surveillance (PMS) evaluating real-world effectiveness and safety of eculizumab in adults with anti-acetylcholine receptor antibody-positive (AChR-Ab+) gMG.
Authors
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Mitsuru Watanabe (ORCID: https://orcid.org/0000-0003-0831-623X)
- Masayuki Masuda (ORCID: https://orcid.org/0000-0002-6175-8902)
- Masaki OKUDA
- Tomoaki Tezuka
- Masanori Mizuno (ORCID: https://orcid.org/0000-0001-5483-4957)
- Takayuki Kondo (ORCID: https://orcid.org/0000-0002-6098-5708)
- Hiroyuki Murai (ORCID: https://orcid.org/0000-0003-1612-1440)
- Masanori Takahashi (ORCID: https://orcid.org/0000-0002-5513-5012)
- Norihiro Suzuki (ORCID: https://orcid.org/0000-0002-0399-6590)
Institutions
- Kansai Medical University (JP)
- Kyushu University (JP)
- Tokyo Medical University (JP)
- Keio University (JP)
- University Medical Center (US)
- Saiseikai Utsunomiya hospital (JP)
- National Hospital Organization Hanamaki Hospital (JP)
- Alexion Pharma (Switzerland) (CH)
- International University of Health and Welfare (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208774
- Citations
- 1
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 1.39